Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60–428) versus 85 (49–156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients. Meropenem/clavulanate is safe and more effective than imipenem/clavulanate in treating MDR and XDR-TB patients http://ow.ly/Z4S2o

[1]  Alimuddin Zumla,et al.  Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB , 2016, European Respiratory Journal.

[2]  E. Pontali,et al.  Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence , 2016, European Respiratory Journal.

[3]  J. Kosterink,et al.  Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis , 2016, European Respiratory Journal.

[4]  A. Diacon,et al.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis , 2015, European Respiratory Journal.

[5]  G. Migliori,et al.  The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases , 2015, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[6]  G. Sotgiu,et al.  Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience , 2015, European Respiratory Journal.

[7]  Simon Tiberi,et al.  Tuberculosis elimination, patients' lives and rational use of new drugs: revisited , 2015, European Respiratory Journal.

[8]  H. Cox,et al.  Compassionate and optimum use of new tuberculosis drugs. , 2015, The Lancet. Infectious diseases.

[9]  J. Caminero,et al.  Classification of antituberculosis drugs: a new proposal based on the most recent evidence , 2015, European Respiratory Journal.

[10]  D. Palmero,et al.  Primera serie de pacientes con TB-XDR y pre-XDR tratados con esquemas que incluyeron meropenem-clavulanato en Argentina , 2015 .

[11]  D. Menzies,et al.  Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment , 2015, European Respiratory Journal.

[12]  G. Maartens,et al.  Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  S. Vesenbeckh,et al.  Mefloquine as a potential drug against multidrug-resistant tuberculosis , 2015, European Respiratory Journal.

[14]  Francesco Castelli,et al.  Towards tuberculosis elimination: an action framework for low-incidence countries , 2015, European Respiratory Journal.

[15]  E. Caumes,et al.  Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  E. Pontali,et al.  Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios , 2015, European Respiratory Journal.

[17]  H. Mauch,et al.  Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains , 2015, European Respiratory Journal.

[18]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[19]  F. Blasi,et al.  ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use , 2014, European Respiratory Journal.

[20]  J. Mainardi,et al.  In Vitro Cross-Linking of Mycobacterium tuberculosis Peptidoglycan by l,d-Transpeptidases and Inactivation of These Enzymes by Carbapenems , 2013, Antimicrobial Agents and Chemotherapy.

[21]  J. Kosterink,et al.  Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis , 2013, European Respiratory Journal.

[22]  Simon Tiberi,et al.  Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use , 2013, European Respiratory Journal.

[23]  R. Diel,et al.  Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation , 2013, European Respiratory Journal.

[24]  A. Spanevello,et al.  Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence , 2013, European Respiratory Journal.

[25]  F. Drobniewski,et al.  Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. , 2013, The Journal of antimicrobial chemotherapy.

[26]  J. Kosterink,et al.  Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[27]  T. Holtz,et al.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes , 2012, European Respiratory Journal.

[28]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[29]  Sonya S. Shin,et al.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis , 2012, European Respiratory Journal.

[30]  V. Leimane,et al.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis , 2012, European Respiratory Journal.

[31]  Giovanni Sotgiu,et al.  Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.

[32]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[33]  T. Shim,et al.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis , 2012, European Respiratory Journal.

[34]  N. Clumeck,et al.  Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  G. Sotgiu,et al.  On linezolid efficacy and tolerability , 2012, European Respiratory Journal.

[36]  R. Diel,et al.  Tuberculosis: cost of illness in Germany , 2012, European Respiratory Journal.

[37]  A. Skrahina,et al.  Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk , 2011, European Respiratory Journal.

[38]  G. Sotgiu,et al.  Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis , 2011, European Respiratory Journal.

[39]  J. Mainardi,et al.  Activity of Carbapenems Combined with Clavulanate against Murine Tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[40]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[41]  G. Sotgiu,et al.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis , 2009, European Respiratory Journal.

[42]  J. Blanchard,et al.  Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis , 2009, Science.

[43]  J. Blanchard,et al.  Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. , 2007, Biochemistry.

[44]  G. Migliori,et al.  First tuberculosis cases in Italy resistant to all tested drugs. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[45]  P. Hopewell,et al.  Imipenem for Treatment of Tuberculosis in Mice and Humans , 2005, Antimicrobial Agents and Chemotherapy.

[46]  C. Chan,et al.  Do β-lactam-β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? , 1995 .

[47]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[48]  N. Clumeck,et al.  Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[49]  W. Yew,et al.  Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.